BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 32701143)

  • 1. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
    Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
    Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
    BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms.
    Zhou X; Liao X; Wang X; Huang K; Yang C; Yu T; Han C; Zhu G; Su H; Han Q; Chen Z; Huang J; Gong Y; Ruan G; Ye X; Peng T
    Cancer Med; 2020 Feb; 9(3):859-871. PubMed ID: 31808619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis.
    Manoochehri M; Wu Y; Giese NA; Strobel O; Kutschmann S; Haller F; Hoheisel JD; Moskalev EA; Hackert T; Bauer AS
    Mol Oncol; 2020 Jun; 14(6):1252-1267. PubMed ID: 32243066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma.
    Chen X; Yu S; Chen J; Chen X
    Cancer Immunol Immunother; 2024 Jun; 73(8):149. PubMed ID: 38833018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low expression of TBX4 predicts poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.
    Zong M; Meng M; Li L
    Int J Mol Sci; 2011; 12(8):4953-63. PubMed ID: 21954337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling.
    Nones K; Waddell N; Song S; Patch AM; Miller D; Johns A; Wu J; Kassahn KS; Wood D; Bailey P; Fink L; Manning S; Christ AN; Nourse C; Kazakoff S; Taylor D; Leonard C; Chang DK; Jones MD; Thomas M; Watson C; Pinese M; Cowley M; Rooman I; Pajic M; ; Butturini G; Malpaga A; Corbo V; Crippa S; Falconi M; Zamboni G; Castelli P; Lawlor RT; Gill AJ; Scarpa A; Pearson JV; Biankin AV; Grimmond SM
    Int J Cancer; 2014 Sep; 135(5):1110-8. PubMed ID: 24500968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
    Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
    Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
    Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
    Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.
    Xue YZ; Wu TL; Wu YM; Sheng YY; Wei ZQ; Lu YF; Yu LH; Li JP; Li ZS
    Tumour Biol; 2013 Oct; 34(5):2857-61. PubMed ID: 23681804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
    Zhao L; Cui Q; Lu Z; Chen J
    Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma.
    Xu R; Xu Q; Huang G; Yin X; Zhu J; Peng Y; Song J
    Biomed Res Int; 2019; 2019():9379864. PubMed ID: 31956659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients.
    Singh N; Rashid S; Rashid S; Dash NR; Gupta S; Saraya A
    J Cancer Res Clin Oncol; 2020 Apr; 146(4):897-907. PubMed ID: 32146565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
    Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
    Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic cancer survival analysis defines a signature that predicts outcome.
    Raman P; Maddipati R; Lim KH; Tozeren A
    PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.
    Nishizawa N; Harada H; Kumamoto Y; Kaizu T; Katoh H; Tajima H; Ushiku H; Yokoi K; Igarashi K; Fujiyama Y; Okuwaki K; Iwai T; Watanabe M; Yamashita K
    Cancer Sci; 2019 Sep; 110(9):2846-2855. PubMed ID: 31325200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer.
    Liu M; Qin Y; Hu Q; Liu W; Ji S; Xu W; Fan G; Ye Z; Zhang Z; Xu X; Yu X; Zhuo Q
    Cancer Lett; 2021 Feb; 499():265-278. PubMed ID: 33232789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma.
    Lu H; Niu F; Liu F; Gao J; Sun Y; Zhao X
    Cancer Med; 2017 Jun; 6(6):1181-1191. PubMed ID: 28440066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.